Table 1.
Characteristics of the study patient population at the time of CMV-TCIP
| Parameter | Patients (N = 37) |
CMV events (N = 16) |
No CMV events (N = 28) |
|---|---|---|---|
| Age (years) (mean ± SD) | 56.4 ± 15.4 | 51.5 ± 17.7 | 57.9 ± 13.6 |
| Women (%) | 15 (40.5) | 9 (56.3) | 12 (42.8) |
| SOT (%) | 31 (83.7) | 15 (93.7) | 23 (82.2) |
| Kidney (%) | 20 (54.1) | 9 (56.3) | 15 (53.6) |
| Kidney-pancreas (%) | 2 (5.4) | 1 (6.3) | 1 (3.5) |
| Heart (%) | 6 (16.2) | 4 (25) | 5 (17.9) |
| Lung (%) | 2 (5.4) | 1 (6.3) | 1 (3.5) |
| Liver (%) | 1 (2.7) | 0 (0) | 1 (3.5) |
| High-risk for CMV (CMV D+/R-) (%) | 20 (54.1) | 12 (75) | 14 (50)* |
| Time from transplant (months) (median, IQR) | 11.9 (7.1–17.2) | 10.2 (8.3–18.5) | 12 (7–16.7) |
| Induction immunosuppression | |||
| Thymoglobulin (%) | 6 (16.2) | 4 (25) | 5 (17.9) |
| Alemtuzumab (%) | 6 (16.2) | 2 (12.5) | 4 (14.2) |
| Basiliximab (%) | 16 (43.2) | 8 (50) | 11 (39.3) |
| None (%) | 1 (2.7) | 0 (0) | 1 (3.5) |
| Unknown (%) | 2 (5.4) | 1 (6.3) | 2 (7.1) |
| Maintenance immunosuppression | |||
| 2 agents (%) | 12 (32.4) | 6 (37.5) | 9 (32.1) |
| 3 agents (%) | 19 (51.3) | 9 (56.3) | 14 (50) |
| High-dose mycophenolate (%)a | 5 (13.5) | 2 (12.5) | 4 (14.2) |
| Tacrolimus trough level (ng/dL) (mean ± SD) | 8.2 ± 4.2 | 8.6 ± 4.9 | 7.9 ± 3.8 |
| Prednisone > 5 mg daily (%) | 15 (40.5) | 4 (25) | 13 (46.4) |
| Non-SOT (%) | 6 (16.2) | 1 (6.3) | 5 (17.8) |
| ALC (109/Lt) (mean ± SD) | 1 ± 0.79 | 1 ± 0.88 | 1 ± 0.76 |
Data are presented as absolute number (% within column) for categorical variables and mean ± standard deviation (SD) or median (interquartile range, IQR) for continuous variables with a normal or non-normal distribution, respectively
ALC Absolute lymphocyte count, CMV D+/R- Donor positive-recipient negative CMV seropositivity status, SOT Solid organ transplant
*P = 0.1
aMycophenolic acid 720 mg or mycophenolate mofetil 1 g twice daily